Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis

Researchers from Denmark published 12-month follow-up data from their ongoing, single-arm, phase 2 COMBI trial of low-dose pegylated interferon alfa-2 plus ruxolitinib in patients with low- to intermediate-risk myelofibrosis (MF) or polycythemia vera (PV), showing complete or partial remission and sustained complete hematologic responses (CHR) in 17% and 22% of patients with MF, respectively, and partial remission and CHR in 9% and 47% of PV patients, respectively.

Cancer Medicine